11 Apr. 2019
BIOVERSYS AG AND APTUIT ANNOUNCE COLLABORATION
BioVersys AG and Aptuit have announced the start of their joint collaboration to identify novel approaches to treat serious infections from gram-negat...
11 Apr. 2019
WHO STRESSES URGENT NEED FOR R&D FOR DRUG-RESISTANT TB ALONGSIDE NEWLY-PRIORITIZED ANTIBIOTIC-RESISTANT PATHOGENS
WHO reaffirms the critical need for research and development (R&D) of new antibiotics to tackle the threat of drug-resistant tuberculosis (TB)....
11 Apr. 2019
DEADLY, DRUG-RESISTANT 'SUPERBUGS' POST HUGE THREAT WHO SAYS
The World Health Organization warned on Monday that a dozen antibiotic-resistant “superbugs” pose an enormous threat to human health, and urged hospit...
11 Apr. 2019
WHO PUBLISHES FIRST EVER LIST OF ANTIBIOTIC-RESISTANT "PRIORITY PATHOGENS"
WHO today published its first ever list of antibiotic-resistant "priority pathogens" – a catalogue of 12 families of bacteria that pose the greatest t...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
